


**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:


1. (Currently amended) A compound of Formula (I) or a salt, or solvate,  
~~or physiologically functional derivative thereof:~~



(I)

wherein:


- R1 is hydrogen or C<sub>1-6</sub>alkyl or as indicated by the dotted line is fused to the phenyl forming a 5 or 6 membered ring, optionally containing a double bond;
- n is 0, 1, 2, 3 or 4;
- R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen, NH<sub>2</sub>, hydroxy, cyano, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, aryl, aryloxy, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulfonyl and a group R<sub>3</sub>R<sub>4</sub>NSO<sub>2</sub> (wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or C<sub>1-4</sub>alkyl), (CH<sub>2</sub>)<sub>0-3</sub>NHCOOC<sub>1-4</sub>alkyl, and a 5- or 6-membered heteroaryl group;
- or n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 5- or 6-membered monocyclic heterocyclic ring or a 9- or 10-membered bicyclic heterocyclic ring wherein at least the ring which contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, and wherein the 5- or 6-membered monocyclic heterocyclic ring or the 9- or 10-membered bicyclic heterocyclic ring is optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, cyano, oxo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, aryl, aryloxy and C<sub>1-4</sub>alkoxycarbonyl; and
- X is indazolyl, pyrazolyl or a group



wherein


G is CH or N; and

$Y_1$  and  $Y_2$  are independently hydrogen, halogen and a group NR<sub>5</sub>R<sub>6</sub> (wherein R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, or



2. (Original) A compound as claimed in claim 1, wherein R<sub>1</sub> is hydrogen.
3. (Currently amended) A compound as claimed in claim 1 ~~or claim 2~~, wherein n is 1 or 2.
4. (Currently amended) A compound as claimed in claim 1 ~~any of claims 1-3~~, wherein R<sub>2</sub> is aryl, optionally substituted by one or two groups selected from the group consisting of halogen and C<sub>1-4</sub>alkoxy.
5. (Currently amended) A compound as claimed in claim 1 ~~or claim 2~~, wherein n is 0 and R<sub>1</sub> and R<sub>2</sub>, together with the nitrogen atom to which they are joined, form a 6-membered monocyclic heterocyclic ring or a 10-membered bicyclic heterocyclic ring wherein at least the ring which each contains the nitrogen atom to which R<sub>1</sub> and R<sub>2</sub> are joined is non-aromatic, wherein the 6-membered monocyclic heterocyclic ring or 10-membered bicyclic heterocyclic ring are both optionally substituted by one or two groups selected from oxo, C<sub>1-4</sub>alkyl, phenyl and C<sub>1-4</sub>alkoxycarbonyl.
6. (Currently amended) A compound as claimed in claim 1 ~~any of claims 1-5~~, wherein X is indazolyl or pyrazolyl.


7. (Currently amended) A compound as claimed in claim 1 ~~any of claims~~



~~4-5~~, wherein X is a group:

wherein Y<sub>1</sub> is hydrogen or halogen.

8. (Currently amended) A compound as claimed in claim 1 ~~any of claims 1-5~~, wherein X is a group:



wherein one of Y<sub>1</sub> and Y<sub>2</sub> is hydrogen, and the other is hydrogen, halogen or a group NR<sub>5</sub>R<sub>6</sub> wherein R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, C<sub>1-6</sub>alkyl or C<sub>2-6</sub>alkenyl.

9. (Currently amended) A compound as claimed in claim 1, wherein said compound is selected from the group consisting of ~~which is:~~

N-benzyl-4-(4-pyridinyl)benzamide;  
 N-(2-phenylethyl)-4-(4-pyridinyl)benzamide;  
 N-(3-methoxybenzyl)-4-(4-pyridinyl)benzamide;  
 N-(3-methoxybenzyl)-4-(1H-pyrazol-4-yl)benzamide;  
 4-(2-chloro-4-pyridinyl)-N-(3-methoxybenzyl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)benzamide;  
 N-(3-methoxybenzyl)-4-(4-pyrimidinyl)benzamide;  
 4-[6-(allylamino)-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide;  
 4-[6-amino-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide;  
 4-(1H-indazol-5-yl)-N-(3-methoxybenzyl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[[3-(methoxy)phenyl]methyl]benzamide;  
 4-(2-[[4-(methoxy)phenyl]amino]-4-pyrimidinyl)-N-[[3-(methoxy)phenyl]methyl]benzamide;

4-(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(4-chlorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(2-fluorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[[2-(methyloxy)phenyl]methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(2-methylphenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[[4-(methyloxy)phenyl]methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]benzamide;  
 1,1-dimethylethyl{3-[[4-(2-amino-4-pyrimidinyl)phenyl]carbonyl]amino)methyl]phenyl)methyl}carbamate;  
 4-(2-amino-4-pyrimidinyl)-N-[(3-bromophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(3-fluorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-[4-(methyloxy)phenyl]ethyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]benzamide;  
 6-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-1(2H)-isoquinolinone;  
 4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-({3-[(difluoromethyl)oxy]phenyl}methyl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-(4-biphenyl)methyl]benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]benzamide;  
 1,1-dimethylethyl{3-[1-[[4-(2-amino-4-pyrimidinyl)phenyl]carbonyl]amino)ethyl]phenyl}carbamate;  
 N-[(2-aminophenyl)methyl]-4-(2-amino-4-pyrimidinyl)benzamide;  
 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;  
 5-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;  
 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-[3-(methyloxy)phenyl]ethyl]benzamide; and  
 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]benzamide;

or a salt, or solvate ~~or physiologically functional derivative~~ thereof.

10-11. (Cancelled).

12. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate ROCK-1 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as defined in claim 1~~any of claims 1-9~~.

13. (Cancelled).

14. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1~~any of claims 1-9~~ and one or more of pharmaceutically acceptable carriers, diluents and excipients.